School of Nursing University of Minnesota Minneapolis MN.
College of Education, Health, and Human Sciences University of Tennessee Knoxville TN.
J Am Heart Assoc. 2023 Sep 5;12(17):e031182. doi: 10.1161/JAHA.123.031182. Epub 2023 Aug 29.
Background Overweight and obesity are associated with adverse functional outcomes in people with peripheral artery disease (PAD). The effects of weight loss in people with overweight/obesity and PAD are unknown. Methods The PROVE (Promote Weight Loss in Obese PAD Patients to Prevent Mobility Loss) Trial is a multicentered randomized clinical trial with the primary aim of testing whether a behavioral intervention designed to help participants with PAD lose weight and walk for exercise improves 6-minute walk distance at 12-month follow-up, compared with walking exercise alone. A total of 212 participants with PAD and body mass index ≥25 kg/m will be randomized. Interventions are delivered using a Group Mediated Cognitive Behavioral intervention model, a smartphone application, and individual telephone coaching. The primary outcome is 12-month change in 6-minute walk distance. Secondary outcomes include total minutes of walking exercise/wk at 12-month follow-up and 12-month change in accelerometer-measured physical activity, the Walking Impairment Questionnaire distance score, and the Patient-Reported Outcomes Measurement Information System mobility questionnaire. Tertiary outcomes include 12-month changes in perceived exertional effort at the end of the 6-minute walk, diet quality, and the Short Physical Performance Battery. Exploratory outcomes include changes in gastrocnemius muscle biopsy measures of mitochondrial cytochrome C oxidase activity, mitochondrial biogenesis, capillary density, and inflammatory markers. Conclusions The PROVE randomized clinical trial will evaluate the effects of exercise with an intervention of coaching and a smartphone application designed to achieve weight loss, compared with exercise alone, on walking performance in people with PAD and overweight/obesity. Results will inform optimal treatment for the growing number of patients with PAD who have overweight/obesity. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04228978.
超重和肥胖与外周动脉疾病(PAD)患者的不良功能结局相关。超重/肥胖合并 PAD 患者减肥的效果尚不清楚。
PROVE(促进肥胖 PAD 患者减肥以预防活动能力丧失)试验是一项多中心随机临床试验,主要目的是检验一种旨在帮助 PAD 患者减肥和步行锻炼的行为干预措施是否能改善 12 个月随访时的 6 分钟步行距离,与单独步行锻炼相比。共有 212 名 PAD 且体质指数≥25kg/m2 的患者将被随机分组。干预措施采用团体介导的认知行为干预模式、智能手机应用程序和个体电话辅导进行。主要结局是 12 个月时 6 分钟步行距离的变化。次要结局包括 12 个月时的步行锻炼总分钟数/周、12 个月时加速度计测量的身体活动变化、步行障碍问卷距离评分和患者报告的结局测量信息系统移动问卷。三级结局包括 12 个月时 6 分钟步行结束时感知用力的变化、饮食质量和简短身体表现电池。探索性结局包括腓肠肌活检中线粒体细胞色素 C 氧化酶活性、线粒体生物发生、毛细血管密度和炎症标志物的变化。
PROVE 随机临床试验将评估与单独运动相比,教练和智能手机应用程序干预以实现减肥对超重/肥胖合并 PAD 患者步行能力的影响。结果将为越来越多超重/肥胖合并 PAD 的患者提供最佳治疗信息。